These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27597143)

  • 1. Dynamic dissolution-/permeation-testing of nano- and microparticle formulations of fenofibrate.
    Sironi D; Rosenberg J; Bauer-Brandl A; Brandl M
    Eur J Pharm Sci; 2017 Jan; 96():20-27. PubMed ID: 27597143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential.
    Hens B; Brouwers J; Corsetti M; Augustijns P
    Eur J Pharm Sci; 2015 Sep; 77():40-7. PubMed ID: 26004010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.
    Juenemann D; Jantratid E; Wagner C; Reppas C; Vertzoni M; Dressman JB
    Eur J Pharm Biopharm; 2011 Feb; 77(2):257-64. PubMed ID: 21074611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations.
    Pestieau A; Krier F; Brouwers A; Streel B; Evrard B
    Eur J Pharm Sci; 2016 Sep; 92():212-9. PubMed ID: 27169683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution/permeation: The importance of the experimental setup for the prediction of formulation effects on fenofibrate
    Forner K; Hidalgo I; Lin J; Ackermann M; Langguth P
    Pharmazie; 2017 Oct; 72(10):581-586. PubMed ID: 29441882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
    Suys EJA; Chalmers DK; Pouton CW; Porter CJH
    Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals.
    Zuo B; Sun Y; Li H; Liu X; Zhai Y; Sun J; He Z
    Int J Pharm; 2013 Oct; 455(1-2):267-75. PubMed ID: 23876497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The elucidation of key factors for oral absorption enhancement of nanocrystal formulations: In vitro-in vivo correlation of nanocrystals.
    Imono M; Uchiyama H; Yoshida S; Miyazaki S; Tamura N; Tsutsumimoto H; Kadota K; Tozuka Y
    Eur J Pharm Biopharm; 2020 Jan; 146():84-92. PubMed ID: 31816392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
    O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
    Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a dynamic dissolution/permeation model: Mutual influence of dissolution and barrier-flux under non-steady state conditions.
    Sironi D; Christensen M; Rosenberg J; Bauer-Brandl A; Brandl M
    Int J Pharm; 2017 Apr; 522(1-2):50-57. PubMed ID: 28263834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into the mechanism behind oral bioavailability-enhancement by nanosuspensions through combined dissolution/permeation studies.
    Lynnerup JT; Eriksen JB; Bauer-Brandl A; Holsæter AM; Brandl M
    Eur J Pharm Sci; 2023 May; 184():106417. PubMed ID: 36870578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining in vitro dissolution/permeation with microdialysis sampling: Capabilities and limitations for biopharmaceutical assessments of supersaturating drug formulations.
    Holzem FL; Jensen IH; Petrig Schaffland J; Stillhart C; Brandl M; Bauer-Brandl A
    Eur J Pharm Sci; 2023 Sep; 188():106533. PubMed ID: 37480963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate.
    Dressman JB; Herbert E; Wieber A; Birk G; Saal C; Lubda D
    J Pharm Pharmacol; 2016 May; 68(5):634-45. PubMed ID: 26255860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel microdialysis-dissolution/permeation system for testing oral dosage forms: A proof-of-concept study.
    Fong SYK; Poulsen J; Brandl M; Bauer-Brandl A
    Eur J Pharm Sci; 2017 Jan; 96():154-163. PubMed ID: 27644896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution/permeation with PermeaLoop™: Experience and IVIVC exemplified by dipyridamole enabling formulations.
    Eriksen JB; Messerschmid R; Andersen ML; Wada K; Bauer-Brandl A; Brandl M
    Eur J Pharm Sci; 2020 Nov; 154():105532. PubMed ID: 32871215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability.
    Ige PP; Baria RK; Gattani SG
    Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.
    Do TT; Van Speybroeck M; Mols R; Annaert P; Martens J; Van Humbeeck J; Vermant J; Augustijns P; Van den Mooter G
    Int J Pharm; 2011 Jul; 414(1-2):118-24. PubMed ID: 21596119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manufacturing nanosized fenofibrate by salt assisted milling.
    Mochalin VN; Sagar A; Gour S; Gogotsi Y
    Pharm Res; 2009 Jun; 26(6):1365-70. PubMed ID: 19224343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The artificial membrane insert system as predictive tool for formulation performance evaluation.
    Berben P; Brouwers J; Augustijns P
    Int J Pharm; 2018 Feb; 537(1-2):22-29. PubMed ID: 29241703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.